Anja Feldmann

Dr. Anja Feldmann serves as the Head of the Radioimmunology Department at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR). She leads research in cancer immunotherapy, focusing on modular and switchable CAR T-cell platforms for targeted treatment of solid tumors and hematological malignancies. Her work integrates cutting-edge technologies like biosensors and theranostic tools to enhance therapeutic efficacy and overcome immune escape mechanisms.

Her research interests revolve around developing universal chimeric antigen receptor (UniCAR) systems and their adaptability for personalized immunotherapy. Key areas include the design of target modules for CAR T/NK cells, combining immunotherapy with radiation, and creating diagnostic tools such as extended-gate field-effect transistors (FET) biosensors to monitor drug responses. She also explores applications in autoimmune diseases and oncology, emphasizing safety and precision in therapeutic approaches.

Dr. Feldmann’s recent advancements include overcoming antigen loss in tumors via dual targeting and improving CAR T-cell persistence through affinity optimization. Her lab’s work on RevCAR systems demonstrates innovation in redirecting T cells to immunosuppressive markers like PD-L1, turning them into activating signals.

Despite no explicit mention of scientific awards, her contributions to CAR T-cell engineering and theranostics are highlighted through collaborations and preclinical studies. She oversees projects involving clinical scale manufacturing, off-the-shelf NK cell therapies, and interdisciplinary approaches to cancer management. Her team’s efforts span from lab-scale innovations to translational research, aiming to bridge gaps between diagnostics and treatment.